Payment overview · 2025
General Payments
$31.15
2 reported records · 2 companies
Healthcare provider profile · identity verified
David Jonathan Budhoo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ANDERSON, SC · NPI 1821251240
Verified facts
What the public records show
CMS Open Payments records show David Jonathan Budhoo, M.D. received $31.15 in general payments during 2025 across 2 reported records.
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) accounted for 53.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $16.67 | 53.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.48 | 46.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $31.15 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
84 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 120 |
| Eliquis | Apixaban | 436 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 393 | 59 |
| Furosemide | Furosemide | 365 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 271 | 54 |
| Gabapentin | Gabapentin | 243 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 240 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 229 | 57 |
| Carvedilol | Carvedilol | 192 | 52 |
| Levetiracetam | Levetiracetam | 169 | 36 |
| Potassium Chloride | Potassium Chloride | 166 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 33 |
| Divalproex Sodium | Divalproex Sodium | 144 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 37 |
| Trulicity | Dulaglutide | 133 | suppressed |
| Lisinopril | Lisinopril | 123 | 32 |
| Metformin Hcl | Metformin Hcl | 122 | 24 |
| Losartan Potassium | Losartan Potassium | 100 | 34 |
| Buspirone Hcl | Buspirone Hcl | 99 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 98 | 23 |
| Trazodone Hcl | Trazodone Hcl | 98 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 96 | 47 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 19 |
| Montelukast Sodium | Montelukast Sodium | 90 | 17 |
| Sertraline Hcl | Sertraline Hcl | 86 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 84 | 22 |
| Xarelto | Rivaroxaban | 84 | 12 |
| Memantine Hcl | Memantine Hcl | 83 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 81 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 78 | 24 |
| Finasteride | Finasteride | 76 | 13 |
| Sucralfate | Sucralfate | 72 | suppressed |
| Movantik | Naloxegol Oxalate | 68 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 15 |
| Midodrine Hcl | Midodrine Hcl | 61 | 19 |
| Jardiance | Empagliflozin | 60 | suppressed |
| Mirtazapine | Mirtazapine | 60 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 59 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | 15 |
| Novolog Flexpen | Insulin Aspart | 53 | 11 |
| Baclofen | Baclofen | 52 | suppressed |
| Ezetimibe | Ezetimibe | 51 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Latanoprost | Latanoprost | 48 | 13 |
| Spironolactone | Spironolactone | 47 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 23 |
| Glipizide | Glipizide | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 27 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 19 |
| Brimonidine Tartrate | Brimonidine Tartrate | 36 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 13 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 33 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Prednisone | Prednisone | 32 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 28 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Omeprazole | Omeprazole | 28 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Verquvo | Vericiguat | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 19 |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Cephalexin | Cephalexin | 20 | 14 |
| Fluconazole | Fluconazole | 20 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Lactulose | Lactulose | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Aristada | Aripiprazole Lauroxil | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | 12 |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $31.15 · 2 records | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest, SPRAVATO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error